Flutamide (2-methyl-N-[4-nitoro-3(trifluoromethyl)phenyl]propanamide) is a non-steroidal antiandrogen which behaves as a competitive agonist of the androgen receptor.
Flutamide is well recognized as a beneficial compound for the treatment of prostate cancer when used in combination with luteinizing hormone-releasing hormone agonists or orchiectomy. [4] [5] [6] This antiandrogen is also used in the treatment of hirsutism and benign prostatic hyperplasia. 7, 8) Despite its proven utility, however, there has been growing concern about an association between flutamide and hepatotoxicity in humans. [9] [10] [11] [12] [13] Flutamide-induced hepatic dysfunction is considered to be a consequence of its biotransformation into electrophilic metabolites by cytochrome P450s (CYPs). 14, 15) These reactive metabolites likely bind to microsomal proteins, leading to either toxic or immune hepatitis in patients. 14, 15) Although a nitro anion free radical was found to be a reactive metabolite of a flutamide-related antiandrogen nilutamide, 16 ) the radical formation was not detected in the flutamide metabolites. 14) Instead, flutamide was reported to be oxidatively metabolized by human CYP3A and 1A subfamilies into chemically reactive species, 14) but the causal metabolite for flutamide-induced hepatotoxicity has not yet been identified.
Differences in frequencies of flutamide-related hepatotoxicity have been observed between reports from Japanese and Western patients. [9] [10] [11] [12] Frequencies of hepatotoxicity in Western patients were reported to range from less than 1 to 10%. 9, 10) Despite the clinical dose of flutamide for Japanese patients being only half that for Westerners, a higher incidence of hepatotoxicity has been seen in the former group. [11] [12] [13] The difference seems attributable to ethnic differences in the frequency of genetic polymorphism in drug metabolizing enzymes. If this view is correct, flutamide metabolites in the serum could be unique to the incidence group.
It has been reported that elevated alanine aminotransferase (ALT) levels and past history of liver disorders were associated with an incidence of flutamide-induced hepatotoxicity. 12) Monitoring of serum aspartate aminotransferase (AST) and ALT levels during flutamide treatment is also known to be effective to obviate serious hepatotoxicity. 10, 12) Unfortunately, more specific predictors of which patients are at risk for flutamide-induced hepatotoxicity are not now available. If a measurement of flutamide metabolites in serum at the initial administration could predict those patients at risk for hepatotoxicity, the drug could be more comfortably used. In the present study, we screened the pattern of flutamide metabolites in serum from 15 patients administered flutamide, and the metabolite profiles from those showing hepatic dysfunction were compared with those from normal patients. Table 1 . In three patients (A, B, C), hepatic dysfunction occurred after the start of flutamide treatment. Blood samples for determination of flutamide metabolites were collected before, and at 2 and 4 h after drug administration. Blood samples were drawn and centrifuged at 4°C, 1000ϫg for 10 min. The serum was transferred into polypropylene tubes for storage at Ϫ80°C until analysis.
MATERIALS AND METHODS

Materials
Extraction of Flutamide and Its Metabolites from Patient Serum A 500 ml of sample was mixed with 2.5 ml of ethyl acetate-toluene mixture (3 : 1, v/v) after the addition of p-hydroxyl n-propyl benzoic acid as an internal standard, and then centrifuged at 1000ϫg for 10 min. The organic layer was separated and evaporated to dryness under reduced pressure. The residue was redissolved in a methanol-water mix- For the determination of conjugates of flutamide or its metabolites, serum (500 ml) was diluted with 1 ml of 0.2 M sodium acetate buffer, pH 5.0 and treated with 500 units of b-glucuronidase at 37°C for 24 h. The resultant mixture was applied to the extraction procedure as described above.
LC/MS Analysis LC/MS analysis was performed on an HP1100 Series LC/MS system (Hewlett Packard, Avondale, PA, U.S.A.). The HPLC/MS system was controlled and data was processed using ChemStation software (Hewlett Packard). HPLC isolation and analysis were carried out on a Waters Puresil TM C18 reversed phase column (4.6ϫ150 mm, 5 mm, Milford, MA, U.S.A.) with a linear gradient of methanol from 30 to 85% over 55 min. The mass spectrometer was operated by an atmospheric pressure chemical ionization (APCI) source in the negative-ion mode. This source was operated at a vaporizer temperature at 350°C, a corona of 30 mA, a capillary voltage of 3 kV, and a nebulizer pressure of 60 psig.
RESULTS
New Metabolite of Flutamide (M3) in Human Serum
Serum of prostatic cancer patients receiving a 375 mg oral dose of flutamide three times a day was withdrawn and flutamide and its metabolites were subjected to LC/MS analysis. A typical total ion current chromatogram of flutamide and its metabolites in the serum shown in Fig. 1 revealed a new metabolite designated as M3, which was detected at the retention time of 17 min. M3 exhibited a molecular ion at m/z 323 and MS/MS analysis of M3 resulted in the production of daughter ions of m/z 205 and 275, suggesting that the structure of M3 was an adduct of oxygen atom to M1 (ϩ16 amu) ( Fig. 2A) . Furthermore, there was a linear relationship between the number of hydroxyl group in flutamide metabolites (flutamide, 2-hydroxyflutamide, M1) and their retention time, and the number in M3 fell on the line (Fig. 2B) . These results strongly indicate that M3 is an oxidized metabolite of flutamide. Similarly, we also found very few oxidized metabolites generated from Flu-2 and Flu-6 in serum (data not shown).
Metabolite Profiles of Flutamide from Patients after Initial Administration
The serum of prostatic cancer patients was taken 4 h after administration of a single oral dose of 125 mg flutamide, and subjected to LC/MS analysis. The relative amount of flutamide metabolites was estimated using the peak area obtained by selected ion monitoring (SIM) mode. Arbitrary ratio of metabolites was calculated from the ratio of each peak area to the sum of peak areas detected as these metabolites. The serum samples were taken from patients in two groups: (1) 12 patients with no sign of hepatotoxicity; and (2) 3 patients with slight increase of the serum levels of AST (63-140 U/l) and ALT (127-189 U/l) during long-term flutamide treatment. As shown in Table 2 , the metabolite profiles did not significantly differ between the two groups.
Since flutamide metabolites are known to be conjugated by glucuronide, the ratio of metabolites in the b-glucuronidasetreated serum was also examined. After b-glucuronidase treatment, Flu-3 and Flu-6 levels were significantly increased compared with those levels before treatment, suggesting that Flu-3 and Flu-6 mainly existed as glucuronide or sulfate conjugates in the serum (Tables 2, 3 ). The metabolite profiles obtained in serum treated with b-glucuronidase also showed no significant differences (Table 3) .
Effect of Ursodeoxycholic Acid (UDCA) on Metabolite Profile of Flutamide in a Patient Recovered from Hepatotoxicity Treatment with UDCA is known to be beneficial for flutamide-induced hepatotoxicity. 17, 18) Since patient A presented with slight increases of AST and ALT levels during long-term flutamide treatment, he was treated with flutamide plus UDCA which resulted in the normalization of these serum clinical markers. To further assess the relationship between flutamide-induced hepatotoxicity and its metabolites, the metabolite profile of patient A treated with flutamide and UDCA was compared with that of patient A treated with flutamide alone. As shown in Fig. 3 , the metabolite profiles of flutamide were not significantly different between the two.
DISCUSSION
We found in this study for the first time that an oxidized metabolite M3 exists in the serum from patients administered flutamide. M3 is suggested to be an oxidized product of M1 on the basis of its molecular mass, production of fragmented ions and relationships of the retention times (Fig. 2) . Although the chemical structures of M1 and M3 remain unidentified, these metabolites contain the structure of flutamide since a fragmented molecular ion at 275 m/z was observed in both metabolites. To examine the enzyme involved in the M3 formation, the metabolic transformation of flutamide was studied using the rat liver microsome-NADPH system in vitro. Three flutamide metabolites (2-hydroxy flutamide, Flu-5, M1) were detected but no M3 formation was observed (data not shown); this may explain the species differences between human and rat in flutamide metabolism.
We profiled flutamide and its metabolites in serum from patients who received long-term flutamide treatment in order to predict the risk for development of flutamide hepatotoxic- ity. However, we failed to find any differences in metabolite profiles between patients suffering flutamide-related hepatotoxicity and control patients. Hence, we judge it difficult to apply the routine evaluation of the metabolite profile to predict risk of flutamide hepatotoxicity. The following possibilities can be envisaged to explain this result. First, since the degree of flutamide-induced liver damage in the patients was slight, we might not find any significant differences between a disordered group and a reference group. Nakagawa et al.
showed that the serum concentration of flutamide was higher in a patient with serious flutamide-induced hepatic disorder than in patients who maintained normal liver function.
11)
Evaluation of the metabolite profile of patients with serious hepatic disorder is expected to be begun in future. Second, structurally dissimilar metabolites are beyond detection in our assay system since analysis by the SIM mode can detect only known metabolites or those containing a substructure of such metabolites. In some cases, free radical species generated during metabolism could cause hepatotoxicity, 16, 19, 20) but these highly reactive species are generally unstable in serum. Therefore, undetected metabolites with recognizable differences between normal and abnormal group might exist in the serum. Third, the metabolites of flutamide would not be the decisive hepatotoxin or inducer of hepatic dysfunction. Fau et al. 15) showed that flutamide by itself created a hepatic damaging effect by inhibiting mitochondrial respiration.
UDCA is a hydrophilic bile acid which ameliorates hepatocellular injury induced by toxic bile salts and is widely used in the treatment of cholestatic liver diseases. The therapeutic potential of UDCA treatment in flutamide-induced hepatotoxicity has also been well recognized. 17) Moreover, in terms of prophylactic effect against flutamide-associated he- patotoxicity, UDCA treatment was reported to be effective in patients with prostate cancer.
18) Hence, we analyzed the metabolite profiles of flutamide in patients with flutamide-related hepatotoxicity receiving flutamide plus UDCA therapy and examined whether the UDCA treatment is associated with the metabolic pattern of flutamide. Unexpectedly, a similar pattern of the profile of flutamide metabolites was observed in the case of treatment with or without UDCA, suggesting the possibility that UDCA has no effect on the flutamide metabolism. In the rat hepatotoxicity induced by coadministration of phenobarbital and flutamide under fasting condition, the serum concentration of flutamide and its metabolites was also unaffected by UDCA treatment. 21) This agrees with our present finding of metabolites in UDCAtreated patients.
The major initial molecular event in flutamide-related hepatotoxicity has been believed to be the formation of electrophilic metabolites mediated by CYP1A and CYP3A, which further reduces the glutathione level. 14, 15) In addition to forming of reactive metabolites, flutamide was reported to inhibit mitochondrial respiration (the electron provision to complex I of the respiratory chain) and then led to generation of reactive oxygen species and ATP depletion. 15) Moreover, the related antiandrogen nilutamide was shown to generate a nitro anion free radical capable of generating toxic reactive species.
16) The feasibility of free radical formation from flutamide was also reported. 14, 22) Although the serum level of M3 did not correlate with the incidence of flutamide-related hepatotoxicity, an undetected reactive metabolite due to its poor stability in serum might be generated through the Recently, it has been reported that measurement of CYP1A2 activity by caffeine test provided a useful means to determine flutamide-related hepatotoxicity. 23) Indeed, flutamide showed a higher cytotoxic effect than 2-hydroxyflutamide in primary rat hepatocytes. 24) Since flutamide is mainly metabolized to its hydroxylated form, 2-hydroxyflutamide by CYP1A2, the decrease in CYP1A2 activity in patients with flutamide-associated hepatotoxicity would result in an increase of serum flutamide level. However, no high level of serum concentration of flutamide was observed in Samples were taken from a patient who had recovered from flutamide-induced hepatotoxicity at the indicated times and were analyzed by LC/MS. Flutamide was orally administered the patient with or without ursodeoxicholic acid. Arbitrary ratio was calculated from the ratio between the MS area of metabolite and the total MS area. 
